Krystal Biotech: Kb-103 Sprints To Become The First Approved Topical Gene Therapy For Skin Disease

Krystal Biotech is currently developing KB-103, an off-the-shelf easily applicable gene therapy for rare congenital skin diseases. If approved, KB-103 will be m


more on seekingalpha.com